Three posters on the anti-KIR program to be presented at the upcoming ASH annual meeting

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces today that three posters on the anti-KIR program will be presented at the upcoming 55th ASH Annual Meeting (December 7-10, 2013) in New Orleans, LA.
 
Two of these posters present data from clinical studies with IPH2101, the hybridoma version of the anti-KIR antibody lirilumab: an extension of the Phase I trial in Acute Myeloid Leukemia and a Phase I trial testing IPH2101 combined with lenalidomide in relapsed Multiple Myeloma. The third poster presents preclinical data demonstrating enhanced efficacy of a cytotoxic antibody when combined with an anti-KIR antibody.
 

Posters will be available at their public presentation on Innate Pharma’s website.